NVCT

Nuvectis is a clinical-stage oncology company with no approved products and no revenue since its 2020 inception, and the MD&A makes the risk plainly: 'We do not have any products approved for sale and have not generated any revenue... We may never be able to develop or commercialize a marketable product.' Every dollar of the -$26.4M FY2025 net loss is R&D and G&A burn, with R&D up 40.5% to $18.2M as trials advance. The accumulated deficit is now -$99.7M against just $18.4M of equity, and operating cash flow was -$16.0M for the year. This is a story stock, and its value rests entirely on a pipeline whose forward picture just got materially worse.

The pivotal disclosure is buried in the MD&A: 'During July 2025, we provided the final clinical data update for NXP800 and decided to cease development activities at this time.' NXP800 — in the clinic since 2021 and the more mature of the two assets — is dead. The entire thesis now rides on NXP900, a single small molecule still in Phase 1a/1b, including a combination study with osimertinib that only commenced in December 2025. That is the earliest, riskiest end of drug development, where the base rate of failure is high and any readout is binary and unknowable from the filing.